NASDAQ:BOLT Bolt Biotherapeutics (BOLT) Stock Forecast, Price & News $1.70 0.00 (0.00%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$1.69▼$1.7550-Day Range$1.29▼$1.9552-Week Range$1.18▼$2.72Volume18,799 shsAverage Volume189,530 shsMarket Capitalization$64.28 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Bolt Biotherapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside194.1% Upside$5.00 Price TargetShort InterestBearish6.40% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.02) to ($1.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector541st out of 983 stocksPharmaceutical Preparations Industry265th out of 486 stocks 3.3 Analyst's Opinion Consensus RatingBolt Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Bolt Biotherapeutics has a forecasted upside of 194.1% from its current price of $1.70.Amount of Analyst CoverageBolt Biotherapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.40% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 6.3.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldBolt Biotherapeutics does not currently pay a dividend.Dividend GrowthBolt Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BOLT. Previous Next 1.1 News and Social Media Coverage Search Interest8 people have searched for BOLT on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.MarketBeat Follows2 people have added Bolt Biotherapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders22.90% of the stock of Bolt Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.13% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($2.02) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bolt Biotherapeutics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bolt Biotherapeutics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBolt Biotherapeutics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bolt Biotherapeutics (NASDAQ:BOLT) StockBolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.Read More Receive BOLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BOLT Stock News HeadlinesMay 26, 2023 | markets.businessinsider.comBolt Biotherapeutics (BOLT) Receives a Buy from H.C. WainwrightMay 13, 2023 | msn.comSVB Leerink Upgrades Bolt Biotherapeutics (BOLT)June 4, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 13, 2023 | msn.comHC Wainwright & Co. Reiterates Bolt Biotherapeutics (BOLT) Buy RecommendationMay 13, 2023 | americanbankingnews.comSVB Leerink Upgrades Bolt Biotherapeutics (NASDAQ:BOLT) to OutperformMay 12, 2023 | markets.businessinsider.comJonesTrading Reaffirms Their Buy Rating on Bolt Biotherapeutics (BOLT)May 12, 2023 | finanznachrichten.deBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateApril 26, 2023 | finance.yahoo.comBolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual MeetingJune 4, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.April 11, 2023 | finance.yahoo.comInvestors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last yearApril 5, 2023 | americanbankingnews.comBrokers Issue Forecasts for Bolt Biotherapeutics, Inc.'s FY2023 Earnings (NASDAQ:BOLT)April 3, 2023 | americanbankingnews.comBolt Biotherapeutics' (BOLT) Buy Rating Reiterated at HC WainwrightApril 2, 2023 | americanbankingnews.comBolt Biotherapeutics (NASDAQ:BOLT) & Endonovo Therapeutics (OTCMKTS:ENDVD) Financial SurveyMarch 31, 2023 | americanbankingnews.comBolt Biotherapeutics, Inc. (NASDAQ:BOLT) Expected to Earn Q1 2023 Earnings of ($0.55) Per ShareMarch 30, 2023 | finanznachrichten.deBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 14, 2023 | finance.yahoo.comBolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual MeetingJanuary 21, 2023 | reuters.comBOLT.O - | Stock Price & Latest News | ReutersJanuary 4, 2023 | finance.yahoo.comHere's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn SituationNovember 2, 2022 | finance.yahoo.comInvestors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 89% over the last yearNovember 1, 2022 | finance.yahoo.comBolt Biotherapeutics to Present at Stifel 2022 Healthcare ConferenceSeptember 10, 2022 | morningstar.comBolt Biotherapeutics Inc Ordinary SharesAugust 31, 2022 | finance.yahoo.comBolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare ConferenceAugust 12, 2022 | benzinga.comBolt Biotherapeutics (NASDAQ:BOLT), Earnings Estimates, EPS, and RevenueMay 26, 2022 | finance.yahoo.comThe past year for Bolt Biotherapeutics (NASDAQ:BOLT) investors has not been profitableMarch 30, 2022 | finance.yahoo.comBolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business HighlightsMarch 30, 2022 | seekingalpha.comBolt Biotherapeutics GAAP EPS of -$0.73 misses by $0.04, revenue of $0.51MMarch 8, 2022 | finance.yahoo.comBolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022See More Headlines BOLT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BOLT Company Calendar Last Earnings3/29/2023Today6/04/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BOLT CUSIP09769810 CIK354655 Webwww.boltbio.com Phone650-665-9295FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+194.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,100,000.00 Net Margins-1,207.36% Pretax Margin-1,207.36% Return on Equity-44.87% Return on Assets-34.65% Debt Debt-to-Equity Ratio0.12 Current Ratio8.10 Quick Ratio8.10 Sales & Book Value Annual Sales$6.74 million Price / Sales9.53 Cash FlowN/A Price / Cash FlowN/A Book Value$4.17 per share Price / Book0.41Miscellaneous Outstanding Shares37,813,000Free Float29,154,000Market Cap$64.28 million OptionableNot Optionable Beta1.02 Key ExecutivesDr. Randall C. Schatzman Ph.D. (Age 68)CEO & Director Comp: $830.67kDr. Edgar G. Engleman M.D. (Age 77)Founder & Independent Director Comp: $31.58kMr. William P. Quinn (Age 52)CFO & Sec. Comp: $563.68kMr. Grant Yonehiro C.F.A. (Age 59)M.B.A., Chief Bus. Officer Comp: $519.98kDr. Edith A. Perez M.D. (Age 66)Chief Medical Officer Comp: $627.32kMs. Karen L. BergmanVP of Communications & Investor RelationsMr. Wesley BurwellVP & Head of HRDr. Nathan Ihle Ph.D.Sr. VP of Pharmaceutical OperationsDr. Ming Yin Ph.D.VP & Head of BiometricsMore ExecutivesKey CompetitorsFortress BiotechNASDAQ:FBIORegulus TherapeuticsNASDAQ:RGLSMolecular TemplatesNASDAQ:MTEMMerrimack PharmaceuticalsNASDAQ:MACKXOMANASDAQ:XOMAView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 169,398 shares on 5/18/2023Ownership: 0.501%Geode Capital Management LLCBought 23,916 shares on 5/16/2023Ownership: 0.471%Renaissance Technologies LLCBought 15,200 shares on 5/12/2023Ownership: 1.208%Charles Schwab Investment Management Inc.Bought 24,712 shares on 5/12/2023Ownership: 0.065%Bailard Inc.Bought 28,500 shares on 5/8/2023Ownership: 0.075%View All Insider TransactionsView All Institutional Transactions BOLT Stock - Frequently Asked Questions Should I buy or sell Bolt Biotherapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BOLT shares. View BOLT analyst ratings or view top-rated stocks. What is Bolt Biotherapeutics' stock price forecast for 2023? 3 Wall Street research analysts have issued 12 month price targets for Bolt Biotherapeutics' shares. Their BOLT share price forecasts range from $3.00 to $8.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 194.1% from the stock's current price. View analysts price targets for BOLT or view top-rated stocks among Wall Street analysts. How have BOLT shares performed in 2023? Bolt Biotherapeutics' stock was trading at $1.30 on January 1st, 2023. Since then, BOLT shares have increased by 30.8% and is now trading at $1.70. View the best growth stocks for 2023 here. When is Bolt Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our BOLT earnings forecast. How were Bolt Biotherapeutics' earnings last quarter? Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) issued its quarterly earnings results on Wednesday, March, 29th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.10. The company earned $1.41 million during the quarter, compared to analysts' expectations of $1.71 million. Bolt Biotherapeutics had a negative trailing twelve-month return on equity of 44.87% and a negative net margin of 1,207.36%. Is Bolt Biotherapeutics a good dividend stock? Bolt Biotherapeutics (NASDAQ:BOLT) pays an annual dividend of $0.36 per share and currently has a dividend yield of 0.00%. What other stocks do shareholders of Bolt Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP). When did Bolt Biotherapeutics IPO? (BOLT) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO. What is Bolt Biotherapeutics' stock symbol? Bolt Biotherapeutics trades on the NASDAQ under the ticker symbol "BOLT." Who are Bolt Biotherapeutics' major shareholders? Bolt Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.21%), JPMorgan Chase & Co. (0.50%), Geode Capital Management LLC (0.47%), Bailard Inc. (0.08%) and Charles Schwab Investment Management Inc. (0.07%). Insiders that own company stock include Edgar Engleman, Holdings A/S Novo, Randall C Schatzman, Vivo Capital Fund Viii, LP and William P Quinn. View institutional ownership trends. How do I buy shares of Bolt Biotherapeutics? Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bolt Biotherapeutics' stock price today? One share of BOLT stock can currently be purchased for approximately $1.70. How much money does Bolt Biotherapeutics make? Bolt Biotherapeutics (NASDAQ:BOLT) has a market capitalization of $64.28 million and generates $6.74 million in revenue each year. The company earns $-88,100,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis. How can I contact Bolt Biotherapeutics? Bolt Biotherapeutics' mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.boltbio.com. The company can be reached via phone at 650-665-9295 or via email at sarah.mccabe@sternir.com. This page (NASDAQ:BOLT) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.